|
1.
|
Masuda T, Marugame T, Kamo K, Katanoda K,
Ajiki W and Sobue T; Japan Cancer Surveillance Research Group:
Cancer incidence and incidence rates in Japan in 2003: based on
data from 13 population-based cancer registries in the Monitoring
of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol.
39:850–858. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Minami Y, Tsubono Y, Nishino Y, Ohuchi N,
Shibuya D and Hisamichi S: The increase of female breast cancer
incidence in Japan: emergence of birth cohort effect. Int J Cancer.
108:901–906. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
|
|
5.
|
Kwan ML, Kushi LH, Weltzien E, Maring B,
Kutner SE, Fulton RS, Lee MM, Ambrosone CB and Caan BJ:
Epidemiology breast cancer subtypes in two prospective cohort
studies of breast cancer survivors. Breast Cancer Res. 11:R312009.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Strategies for subtypes-dealing with
the diversity of breast cancer: highlights of the St. Gallen
International Expert Consensus on the Primary Therapy of Early
Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Rakha EA, El-Rehim DA, Paish C, Green AR,
Lee AH, Robertson JF, Blamey RW, Macmillan D and Ellis IO: Basal
phenotype identifies a poor prognostic subgroup of breast cancer of
clinical importance. Eur J Cancer. 42:3149–3156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
|
|
9.
|
Sørlie T, Wang Y, Xiao C, Johnsen H, Naume
B, Samaha RR and Børresen-Dale AL: Distinct molecular mechanisms
underlying clinically relevant subtypes of breast cancer: gene
expression analyses across three different platforms. BMC Genomics.
7:1272006.
|
|
10.
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: a population-based study from the California Cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar
|
|
11.
|
Brown M, Tsodikov A, Bauer KR, Parise CA
and Caggiano V: The role of human epidermal growth factor receptor
2 in the survival of women with estrogen and progesterone
receptor-negative, invasive breast cancer: the California Cancer
Registry, 1999–2004. Cancer. 112:737–747. 2008.PubMed/NCBI
|
|
12.
|
Trivers KF, Lund MJ, Porter PL, Liff JM,
Flagg EW, Coates RJ and Eley JW: The epidemiology of
triple-negative breast cancer, including race. Cancer Causes
Control. 20:1071–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Millikan RC, Newman B, Tse CK, et al:
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat.
109:123–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Phipps AI, Malone KE, Porter PL, Daling JR
and Li CI: Body size and risk of luminal, HER2-overexpressing, and
triple-negative breast cancer in postmenopausal women. Cancer
Epidemiol Biomarkers Prev. 17:2078–2086. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Yang XR, Sherman ME, Rimm DL, Lissowska J,
Brinton LA, Peplonska B, Hewitt SM, Anderson WF,
Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al: Differences in
risk factors for breast cancer molecular subtypes in a
population-based study. Cancer Epidemiol Biomarkers Prev.
16:439–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Iwasaki M, Otani T, Inoue M, Sasazuki S
and Tsugane S; for the Japan Public Health Center-Based Prospective
Study Group: Body size and risk for breast cancer in relation to
estrogen and progesterone receptor status in Japan. Ann Epidemiol.
17:304–312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Suzuki R, Iwasaki M, Inoue M, Sasazuki S,
Sawada N, Yamaji T, Shimazu T and Tsugane S; Japan Public Health
Center-Based Prospective Study Group: Body weight at age 20 years,
subsequent weight change and breast cancer risk defined by estrogen
and progesterone receptor status-the Japan public health
center-based prospective study. Int J Cancer. 129:1214–1224.
2011.
|
|
18.
|
WHO Expert Consultation: Appropriate
body-mass index for Asian populations and its implications for
policy and intervention strategies. Lancet. 363:157–163. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Begg CB and Zhang ZF: Statistical analysis
of molecular epidemiology studies employing case-series. Cancer
Epidemiol Biomarkers Prev. 3:173–175. 1994.PubMed/NCBI
|
|
20.
|
Rich-Edwards JW, Goldman MB, Willett WC,
Hunter DJ, Stampfer ML, Colditz GA and Manson JE: Adolescent body
mass index and infertility caused by ovulatory disorder. Am J
Obstet Gynecol. 171:171–177. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Harvie M, Hooper L and Howell AH: Central
obesity and breast cancer risk: a systematic review. Obes Rev.
4:157–173. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Garofalo C, Koda M, Cascio S, Sulkowska M,
Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S and Surmacz E:
Increased expression of leptin and the leptin receptor as a marker
of breast cancer progression: possible role of obesity-related
stimuli. Clin Cancer Res. 12:1447–1453. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Friedenreich CM: Review of anthropometric
factor and breast cancer risk. Eur J Cancer Prev. 10:15–32. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Renehan AG, Tyson M, Egger M, Heller RF
and Zwahlen M: Body-mass index and incidence of cancer: a
systematic review and meta-analysis of prospective observational
studies. Lancet. 371:569–578. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Miller WR, Hawkins RA and Forrest AP:
Significance of aromatase activity in human breast cancer. Cancer
Res. 42:3365s–3368s. 1982.PubMed/NCBI
|
|
26.
|
Perel E, Wilkins D and Killinger DW: The
conversion of androstenedione to estrone, estradiol, and
testosterone in breast tissue. J Steroid Biochem. 13:89–94. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Sakakura T, Nishizuka Y and Dawe CJ:
Capacity of mammary fat pads of adult C3H/HeMs mice to interact
morphogenetically with fetal mammary epithelium. J Natl Cancer
Inst. 63:733–736. 1979.PubMed/NCBI
|
|
28.
|
Sakakura T, Nishizuka Y and Dawe CJ:
Mesenchyme-dependent morphogenesis and epithelium-specific
cytodifferentiation in mouse mammary gland. Science. 194:1439–1441.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Shyamala G: Progesterone signaling and
mammary gland morphogenesis. J Mammary Gland Biol Neoplasia.
4:89–104. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kalkhoff RK: Metabolic effects of
progesterone. Am J Obstet Gynecol. 142:735–738. 1982.PubMed/NCBI
|
|
31.
|
Russo J, Hu YF, Silva ID and Russo IH:
Cancer risk related to mammary gland structure and development.
Microsc Res Tech. 52:204–223. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Prat A and Perou CM: Mammary development
meets cancer genomics. Nat Med. 15:842–844. 2009. View Article : Google Scholar : PubMed/NCBI
|
